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Background: Various kinase inhibitors are known to be ATP-binding cassette (ABC) transporter substrates and
resistance acquisition to kinase inhibitors has been associated to increased ABC transporter expression. Here, we
investigated the role of the ABC transporters ABCB1, ABCC1, and ABCG2 during melanoma cell resistance acquisition to
the V600-mutant BRAF inhibitors PLX4032 (vemurafenib) and PLX4720. PLX4032 had previously been shown to interfere
with ABCB1 and ABCG2. PLX4720 had been demonstrated to interact with ABCB1 but to a lower extent than PLX4032.
Findings: PLX4032 and PLX4720 affected ABCC1- and ABCG2-mediated drug transport in a similar fashion. In a panel
of 16 V600E BRAF-mutated melanoma cell lines consisting of four parental cell lines and their sub-lines with acquired
resistance to PLX4032, PLX4720, vincristine (cytotoxic ABCB1 and ABCC1 substrate), or mitoxantrone (cytotoxic ABCG2
substrate), we detected enhanced ABC transporter expression in 4/4 cytotoxic ABC transporter substrate-resistant, 3/4
PLX4720-resistant, and 1/4 PLX4032-resistant melanoma cell lines.
Conclusion: PLX4032 has the potential to induce ABC transporter expression but this potential is lower than that of
PLX4720 or cytotoxic ABC transporter substrates. Since ABC transporters confer multi-drug resistance, this is of
relevance for the design of next-line therapies.
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ABCC1, ABCG2Findings
The oncogenic V600-mutant BRAF inhibitor PLX4032
(vemurafenib) caused improved response and survival
rates in V600-mutant BRAF melanoma patients but
PLX4032 resistance formation remains inevitable. Resist-
ance mechanisms involve activation of alternative kinases
and non-related compensatory pathways [1,2]. Although
protein kinase inhibitors are rather specific drugs (parti-
cularly in comparison to the cytotoxic anti-cancer che-
motherapeutics) they are also known to exert off-target
effects [3-5]. For example, different protein kinase in-
hibitors interfere with drug transport mediated by vari-
ous ATP binding cassette (ABC) transporters including* Correspondence: Cinatl@em.uni-frankfurt.de
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unless otherwise stated.ABCB1 (also known as MDR1 or P-glycoprotein), ABCC1
(also known as MRP1), and ABCG2 (also known as
BCRP) [3,4,6-9].
ABC transporters play important roles in the passage
of drugs, xenobiotics, and food constituents through cel-
lular and tissue barriers and consequently in their ab-
sorption, distribution, and excretion. Moreover, different
ABC transporters are frequently found highly expressed
on cancer cells playing an important role in cancer cell
chemoresistance [10-12]. Resistance acquisition to kin-
ase inhibitors may be associated with enhanced ABC
transporter expression on cancer cells [13-15].
Some information is already available on the effects
of PLX4032 and the closely related V600-mutant BRAF
inhibitor PLX4720 [16] on ABC transporter function.
PLX4032 and PLX4720 both interfere with ABCB1-
mediated drug transport [17-19]. PLX4032 was also shownal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ABCG2 expression was suggested to be an acquired re-
sistance mechanism to PLX4032 [20] although data on
ABCG2 expression in cells with acquired PLX4032 re-
sistance are missing.
Recently, we had shown that PLX4032 and PLX4720
differed in their effects on ABCB1-mediated drug trans-
port. Despite the structural similarity of these compounds
PLX4032 interfered stronger with ABCB1 function than
PLX4720 [19]. Here, we 1) compared the effects of
PLX4032 and PLX4720 on ABCG2 and ABCC1 and
2) investigated whether resistance acquisition to these
compounds may be associated with enhanced ABC trans-
porter expression.
Effects of PLX4032 and PLX4720 on ABCG2 and ABCC1
function
To study the effects of PLX4032 and PLX4720 on ABCG2,
an ABCG2-expressing sub-line of the BRAF wild-type































































































Figure 1 Effect of PLX4032 and PLX4720 on ABCG2 activity. A) Influen
UKF-NB-3ABCG2 cells, B) time kinetics of BODIPY-prazosine (1 μM) fluorescen
a 60 min pre-incubation period with subsequent wash-out of extracellular
incubation in the absence of drugs). C) ABCG2 ATPase activity in isolated m
the absence of drugs). Sulfasalazine, a known ABCG2 substrate, was used foused that had been established by lentiviral transduction
with LeGO vectors (www.lentigo-vectors.de) as described
previously [21,22]. All experimental procedures were
performed as described previously [22]. PLX4032 and
PLX4720 treatment of UKF-NB-3ABCG2 cells (but not
of UKF-NB-3 cells or UKF-NB-3 cells transduced with a
control vector) resulted in a similar dose-dependent in-
crease in the cellular accumulation of the fluorescent
ABCG2 substrate BODIPY-prazosine (Figure 1A) without
affecting ABCG2 expression (Additional file 1: Figure S1).
In wash-out experiments, cellular BODIPY-prazosine
fluorescence levels declined rapidly in UKF-NB-3ABCG2
cells (Figure 1B), likely because the removal of extra-
cellular PLX4032 and PLX4720 resulted in the rapid
ABCG2-mediated efflux of PLX4032/PLX4720 and
BODIPY-prazosine. PLX4032 and PLX4720 increased
ABCG2 ATPase activity in an isolated membrane assay
(Figure 1C) indicating binding and activation of ABCG2
by these compounds. Further, PLX4032 and PLX4720





























































































ce of PLX4032 or PLX4720 on BODIPY-prazosine (1 μM) fluorescence in
ce in UKF-NB-3ABCG2 cells in the presence of PLX4032 or PLX4720 after
BODIPY-prazosine and PLX4032 or PLX4720 (control = BODIPY-prazosine
embranes in the presence of PLX4032 or PLX4720 (control = activity in
r comparison. *P < 0.05 relative to non-treated controls.
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but not of non-transduced UKF-NB-3 cells or UKF-NB-3
cells transduced with a control vector (Additional file 2:
Table S1) as indicated by MTT assay after five day incuba-
tion. These findings are in accordance with previous stu-
dies demonstrating PLX4032 to be an ABCG2 substrate
[17,18,20].
The effects of PLX4032 and PLX4720 on ABCC1 were
investigated in the ABCC1-expressing cell lines G62
(glioblastoma) and PC3rVCR20 (prostate cancer) [22].
PLX4032 and PLX4720 similarly increased the accumula-
tion of the fluorescent ABCC1 substrate 5-CFDA in G62
cells in a concentration-dependent manner (Figure 2A)
without affecting ABCC1 expression (Additional file 1:
Figure S1). 5-CFDA fluorescence declined rapidly after
wash-out of PLX4032 or PLX4720 (Figure 2B). Both
substances increased ABCC1 ATPase activity in an iso-
lated membrane assay (Figure 2C) and the toxicity of the











































































































Figure 2 Effect of PLX4032 and PLX4720 on ABCC1 activity. A) Influen
B) time kinetics of 5-CFDA (1 μM) fluorescence in G62 cells in the presence
subsequent wash-out of extracellular 5-CFDA and PLX4032 or PLX4720 (co
activity in isolated membranes in the presence of PLX4032 or PLX4720 (con
substrate, was used for comparison. *P < 0.05 relative to non-treated contro(Additional file 3: Table S2) in a concentration-dependent
manner. These findings appear to contrast other findings
that suggested PLX4032 not to be an ABCC1 substrate
[20]. The differences may be explained by the use of diffe-
rent ABCC1 substrates and different cellular models. De-
pending on the exact mode or strength of interaction of
ABC transporter modulators with an ABC transporter,
different substrates may not always compete for the same
binding site. For example, activators of ABCB1 activity
that enhance the efflux of certain ABCB1 substrates were
described [23]. Moreover, certain ABCB1 modulators were
shown to exert differing effects on the cellular accumula-
tion of distinct ABCB1 substrates [24].
PLX4032 and PLX4720 also sensitised two wild-
type BRAF melanoma cell lines, IPC-298 and SK-Mel-30
(DSMZ, Braunschweig, Germany), that express ABCB1,
ABCC1, and ABCG2 (Additional file 4: Table S3) to vin-
cristine and mitoxantrone (Additional file 5: Table S4).








































































































ce of PLX4032 or PLX4720 on 5-CFDA (1 μM) fluorescence in G62 cells,
of PLX4032 or PLX4720 after a 60 min pre-incubation period with
ntrol = 5-CFDA incubation in the absence of drugs). C) ABCC1 ATPase
trol = activity in the absence of drugs). NEM-GS, a known ABCC1
ls.
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fashion.
ABC transporter expression in V600E BRAF-mutated
melanoma cell lines with acquired resistance to PLX4032
and PLX4720
Next, we investigated the expression of ABCB1, ABCC1,
and ABCG2 in the V600E BRAF-mutated melanoma cell
lines Colo-679, IGR-39, MelHO, and RVH-421 (DSMZ,
Braunschweig, Germany) and their sub-lines with ac-














































Figure 3 Expression of ABCB1, ABCC1, and ABCG2 in V600 BRAF-mut
cytotoxic ABC transporter substrates vincristine (VCR) or mitoxantron
black bars are used to facilitate the identification of resistant sub-lines that
parental cells.MelHOrPLX403210 μM, IGR-39rPLX403220 μM, RVH-
421rPLX403210 μM), PLX4720 (Colo-679rPLX472010 μM,
MelHOrPLX472010 μM, IGR-39rPLX472020 μM, RVH-421r
PLX472010 μM), vincristine (Colo-679rVCR20, IGR-39r
VCR10, MelHOrVCR20), or mitoxantrone (RVH-421r
Mitox10) (Figure 3; Additional file 6: Table S5) that were
derived from the Resistant Cancer Cell Line (RCCL) collec-
tion (www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html).
Treatment of melanoma cells with PLX4032 or cytotoxic
anti-cancer drugs had been shown to result in the selec-
tion of ABCB5-expressing cells [25]. However, we did not relative to respective parental cell line)
1000 1500 2000
 relative to respective parental cell line)
600 800 1000400










ated melanoma cells adapted to PLX4032, PLX4720, or the
e (MITOX) relative to the respective parental cell lines. White and
are derived from the same parental cell line. *P < 0.05 relative to
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dels relative to the parental sensitive cells.
Colo-679rVCR10, MelHOrVCR20, IGR-39rPLX472020 μM,
and RVH-421rPLX472010 μM expressed increased ABCB1
levels, IGR-39rVCR10, IGR-39rPLX403220 μM, and IGR-39r
PLX472020 μM high ABCC1 levels, IGR-39rVCR10, MelHOr
PLX472010 μM, RVH-421rMITOX10, and RVH-421rPLX
472010 μM high ABCG2 levels (Figure 3). The ABC trans-
porters conferred resistance to the cytotoxic ABC trans-
porter substrates vincristine (ABCB1, ABCC1) and
mitoxantrone (ABCG2) but not to PLX4032 or PLX4720
(Additional file 7: Table S6). These data show that V600-
mutant melanoma cells with acquired resistance to
PLX4032 may express enhanced ABC transporter levels.
However, the potential of PLX4032 to induce ABC
transporter expression appears to be lower compared to
PLX4720, although both molecules differ in just one
phenyl group (Additional file 8: Figure S2), and cyto-
toxic ABC transporter substrates.
Discussion
The finding that resistance acquisition to PLX4032 and
PLX4720 may be associated with enhanced ABCB1 ex-
pression is in line with data showing resistance acquisi-
tion to other kinase inhibitors to be associated with
ABCB1, ABCC1, and ABCG2 expression [13-15,26].
PLX4032 had previously been shown to interfere sub-
stantially stronger with ABCB1 than PLX4720 [19] while
we show here that both compounds display similar ef-
fects on ABCG2 and ABCC1. Therefore, differing levels
of interaction with the investigated ABC transporters do
not explain the enhanced ABC transporter expression in
PLX4720-resistant relative to PLX4032-resistant cells.
ABC transporter up-regulation may be part of the cellu-
lar stress response, and anti-cancer drug-induced stress
may induce ABC transporter expression regardless of
whether the drugs are ABC transporter substrates [27-29].
PLX4720 induced more pronounced toxic off-target ef-
fects (IC50 15.04 ± 0.60 μM in BRAF wild-type UKF-NB-3
cells) than PLX4032 (IC50 30.61 ± 1.37 μM in UKF-NB-3).
Also, we detected enhanced ABCG2 expression in
IGR-39rVCR10 cells although vincristine is not regarded
to be an ABCG2 substrate.
In conclusion, we show that PLX4032 and PLX4720
interfere with ABCC1- and ABCG2-mediated drug trans-
port. Since ABC transporters play important roles in the
absorption, distribution, and excretion of drugs these find-
ings are of potential clinical relevance when PLX4032
is co-administered with anti-cancer drugs or non-cancer-
related drugs that are ABC transporter substrates [10-12].
The investigation of a panel of 16 BRAF V600-mutant
melanoma cell lines suggested that resistance acquisition
to PLX4032 may be associated with enhanced ABC trans-
porter expression although PLX4720 and cytotoxic ABCtransporter substrates are stronger inducers of ABC trans-
porter expression than PLX4032. This is of relevance
for the design of next-line therapies for melanomas
with acquired PLX4032 resistance since ABC trans-
porters including ABCB1, ABCC1, and ABCG2 confer
multi-drug resistance [10-12]. The potential clinical
implications of our findings are outlined in Additional
file 9: Figure S3.
Availability of supporting data
The data sets supporting the results of this article are in-
cluded within the article and its additional files.
Additional files
Additional file 1: Figure S1. Effects of PLX4032 and PLX4720 on
ABCG2 and ABCC1 expression. A) ABCG2 expression in UKF-NB-3ABCG2
cells after treatment with PLX4032 or PLX4720 for different incubation
periods in % relative to non-treated control as determined by flow
cytometry; B) ABCC1 expression in G62 cells after treatment with
PLX4032 or PLX4720 for different incubation periods in % relative to
non-treated control as determined by flow cytometry.
Additional file 2: Table S1. A. Influence of PLX4032, PLX4720, or the
ABCG2 inhibitor fumitremorgin C on the concentration of the ABCG2
substrate mitoxantrone that decreases the viability of ABCG2-expressing
UKF-NB-3ABCG2 cells by 50% (IC50). B. Influence of PLX4032 or the ABCG2
inhibitor fumitremorgin C on the concentration of the ABCG2 substrate
mitoxantrone that decreases the viability of UKF-NB-3 cells by 50% (IC50).
C. Influence of PLX4720 or the ABCG2 inhibitor fumitremorgin C on the
concentration of the ABCG2 substrate mitoxantrone that decreases the
viability of UKF-NB-3 cells by 50% (IC50). D. Influence of PLX4032 or the
ABCG2 inhibitor fumitremorgin C on the concentration of the ABCG2
substrate mitoxantrone that decreases the viability of UKF-NB-3 cells
transduced with an empty control vector (as comparison to UKF-NB-
3ABCG2) by 50% (IC50). E. Influence of PLX4720 or the ABCG2 inhibitor
fumitremorgin C on the concentration of the ABCG2 substrate mitoxantrone
that decreases the viability of UKF-NB-3 cells transduced with an empty
control vector (as comparison to UKF-NB-3ABCG2) by 50% (IC50).
Additional file 3: Table S2. A. Influence of PLX4032, PLX4720, or the
ABCC1 inhibitor MK571 on the concentration of the ABCC1 substrate
vincristine that decreases the viability of ABCC1-expressing G62 cells by
50% (IC50). B. Influence of PLX4032 or the ABCC1 inhibitor MK571 on the
concentration of the ABCC1 substrate vincristine that decreases the
viability of ABCC1-expressing PC3rVCR20 cells by 50% (IC50). C. Influence
of PLX4720 or the ABCC1 inhibitor MK571 on the concentration of the
ABCC1 substrate vincristine that decreases the viability of ABCC1-
expressing PC3rVCR20 cells by 50% (IC50).
Additional file 4: Table S3. A. ABCB1 expression in melanoma cells
and the influence of the ABCB1 inhibitor PGP4008 (2.5 μM) on the
concentration of the ABCB1 substrate vincristine that decreases the
viability of melanoma cells by 50% (IC50). B. ABCC1 expression in
melanoma cells and the influence of the ABCC1 inhibitor MK571 (10 μM)
on the concentration of the ABCC1 substrate vincristine that decreases
the viability of melanoma cells by 50% (IC50). C. ABCG2 expression in
melanoma cells and the influence of the ABCG2 inhibitor fumitremorgin
C (10 μM) on the concentration of the ABCG2 substrate mitoxantrone
that decreases the viability of melanoma cells by 50% (IC50).
Additional file 5: Table S4. Influence of PLX4032 (20 μM) or PLX4720
(20 μM) on the vincristine (substrate of ABCB1 and ABCC1) or mitoxantrone
(substrate of ABCG2) concentrations that reduce the cell viability by 50%
(IC50) in the BRAF wild-type melanoma cell lines IPC298 and SK-MEL-30 that
both express ABCB1, ABCC1, and ABCG2.
Additional file 6: Table S5. Drug concentrations that decrease the
viability of V600E BRAFmutated melanoma cells by 50% (IC50).
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http://www.biomedcentral.com/1756-0500/7/710Additional file 7: Table S6. A. Influence of the ABCB1 inhibitor
verapamil (10 μM) on the sensitivity of ABCB1-expressing melanoma cells
to PLX4720 or the cytotoxic ABCB1 substrate vincristine. Concentrations
that reduce the cell viability by 50% (IC50) were determined after a five
day incubation period by MTT assay. B. Influence of the ABCC1 inhibitor
verapamil (10 μM) on the sensitivity of ABCC1-expressing melanoma cells
to PLX4032, PLX4720, or the cytotoxic ABCC1 substrate vincristine.
Concentrations that reduce the cell viability by 50% (IC50) were
determined after a five day incubation period by MTT assay. C. Influence
of ABCG2 inhibitor fumitremorgin C (2.5 μM) on the sensitivity of ABCG2-
expressing melanoma cells to PLX4720 or the cytotoxic ABCG2 substrate
mitoxantrone. Concentrations that reduce the cell viability by 50% (IC50)
were determined after a five day incubation period by MTT assay.
Additional file 8: Figure S2. Chemical structures of PLX4032 and
PLX4720.
Additional file 9: Figure S3. Potential clinical implications of the
findings presented in this report. A) PLX4032 and PLX4720 interfere with
ABCB1, ABCC1, and ABCG2 function. Since these ABC transporters are
expressed at physiological barriers and control the absorption, body
distribution, and excretion of their substrates, inhibition of these
transporters may modify the pharmacokinetics of co-administered
ABC transporter substrates including anti-cancer drugs and drugs that are
administered for alternative indications (e.g. antihypertensive drugs). In
addition, PLX4032 and PLX4720 may sensitise ABC transporter-expressing
cancer cells to co-administered anti-cancer drugs that are ABC transporter
substrates. B) Resistance formation to PLX4032 and PLX4720 may be
associated with enhanced ABC transporter expression in cancer cells. This
enhanced ABC transporter expression will result in cross-resistance of the
PLX4032- or PLX4720-resistant cells to anti-cancer drugs that are
substrates of the respective ABC transporters.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
MM and JCjr designed the study, performed experiments, analysed data, and
drafted the manuscript. FR and TN determined effects of PLX4032 and
PLX4720 on ABC transporter function. MvR established and characterised
drug-resistant melanoma cells. RZ and WGD authenticated and characterised
the investigated cell lines. MW analysed ABC transporter data and provided
WK-X-34. All authors read and approved the final manuscript.
Acknowledgements
The authors thank Kristoffer Riecken and Boris Fehse (Universitätsklinikum
Hamburg-Eppendorf) for provision of and support with the LeGO vectors.
The work was supported by the Hilfe für krebskranke Kinder Frankfurt e.V.
(JCjr, MM), the Frankfurter Stiftung für krebskranke Kinder (JCjr, MM), the
Royal Society (MM), and the Kent Cancer trust (MM).
Author details
1Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul
Ehrlich-Str. 40, Frankfurt am Main 60596, Germany. 2Centre for Molecular
Processing and School of Biosciences, University of Kent, Canterbury Kent
CT2 7NJ, UK. 3Institut für Rechtsmedizin, Klinikum der Goethe-Universität,
Kennedyallee 104, Frankfurt am Main 60596, Germany. 4Leibniz-Institute
Deutsche Sammlung für Mikroorganismen und Zellkulturen GmbH,
Inhoffenstraße 7B, Braunschweig 38124, Germany. 5Pharmaceutical Institute,
University of Bonn, An der Immenburg 4, Bonn 53121, Germany. 6Current
address: Centre for Molecular Processing and School of Biosciences,
University of Kent, Canterbury Kent CT2 7NJ, UK. 7Current address: Institute of
Pharmacology and Toxicology, Biomedical Center (BMZ), University of Bonn,
Bonn 53127, Germany.
Received: 21 August 2014 Accepted: 2 October 2014
Published: 10 October 2014
References
1. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P:
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev
Drug Discov 2012, 11:873–886.2. Bucheit AD, Davies MA: Emerging insights into resistance to BRAF
inhibitors in melanoma. Biochem Pharmacol 2014, 87:381–389.
3. Hegedus C, Ozvegy-Laczka C, Szakács G, Sarkadi B: Interaction of ABC
multidrug transporters with anticancer protein kinase inhibitors:
substrates and/or inhibitors? Curr Cancer Drug Targets 2009, 9:252–262.
4. Van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of
tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35:692–706.
5. Force T, Kolaja KL: Cardiotoxicity of kinase inhibitors: the prediction and
translation of preclinical models to clinical outcomes. Nat Rev Drug Discov
2011, 10:111–126.
6. Hegedus T, Orfi L, Seprodi A, Váradi A, Sarkadi B, Kéri G: Interaction of
tyrosine kinase inhibitors with the human multidrug transporter
proteins, MDR1 and MRP1. Biochim Biophys Acta 2002, 1587:318–325.
7. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T,
Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS: Erlotinib (Tarceva, OSI-774)
antagonizes ATP-binding cassette subfamily B member 1 and
ATP-binding cassette subfamily G member 2-mediated drug resistance.
Cancer Res 2007, 67:11012–11020.
8. Hegedüs C, Ozvegy-Laczka C, Apáti A, Magócsi M, Német K, Orfi L, Kéri G,
Katona M, Takáts Z, Váradi A, Szakács G, Sarkadi B: Interaction of nilotinib,
dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered
anti-cancer effects and pharmacological properties. Br J Pharmacol 2009,
158:1153–1164.
9. Hegedüs C, Truta-Feles K, Antalffy G, Várady G, Német K, Ozvegy-Laczka C,
Kéri G, Orfi L, Szakács G, Settleman J, Váradi A, Sarkadi B: Interaction of the
EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the
ABCG2 multidrug transporter: Implications for the emergence and
reversal of cancer drug resistance. Biochem Pharmacol 2012, 84:260–267.
10. Silverton L, Dean M, Moitra K: Variation and evolution of the ABC
transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8:
implication for pharmacogenetics and disease. Drug Metabol Drug Interact
2011, 26:169–179.
11. Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE: The controversial role
of ABC transporters in clinical oncology. Essays Biochem 2011, 50:209–232.
12. Ieiri I: Functional significance of genetic polymorphisms in P-
glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP,
ABCG2). Drug Metab Pharmacokinet 2012, 27:85–105.
13. Burger H, Van Tol H, Brok M, Wiemer EA, De Bruijn EA, Guetens G, De Boeck
G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure
leads to reduced intracellular drug accumulation by induction of the
ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther
2005, 4:747–752.
14. Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R,
Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH:
Abcg2 overexpression represents a novel mechanism for acquired
resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive
cells in vitro. PLoS One 2011, 6:e19164.
15. Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL,
Hughes TP: Tyrosine kinase inhibitor resistance in chronic myeloid
leukemia cell lines: investigating resistance pathways. Leuk Lymphoma
2011, 52:2139–2147.
16. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong
J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A,
Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C,
Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, et al:
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proc Natl Acad Sci U S A 2008, 105:3041–3046.
17. Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Oral availability
and brain penetration of the B-RAFV600E inhibitor vemurafenib can be
enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance
protein (ABCG2) inhibitor elacridar. Mol Pharm 2012, 9:3236–3245.
18. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF: Impact of P-glycoprotein
(ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the brain
distribution of a novel B-RAF Inhibitor: Vemurafenib (PLX4032). J Pharmacol
Exp Ther 2012, 342:33–40.
19. Michaelis M, Rothweiler F, Nerreter T, Van Rikxoort M, Sharifi M, Wiese M,
Ghafourian T, Cinatl J Jr: Differential effects of the oncogenic BRAF
Inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1
function. J Pharm Pharm Sci 2014, 17:154–168.
20. Wu CP, Sim HM, Huang YH, Liu YC, Hsiao SH, Cheng HW, Li YQ, Ambudkar SV,
Hsu SC: Overexpression of ATP-binding cassette transporter ABCG2 as a
Michaelis et al. BMC Research Notes 2014, 7:710 Page 7 of 7
http://www.biomedcentral.com/1756-0500/7/710potential mechanism of acquired resistance to vemurafenib in BRAF
(V600E) mutant cancer cells. Biochem Pharmacol 2013, 85:325–334.
21. Weber K, Bartsch U, Stocking C, Fehse B: A multicolor panel of novel
lentiviral "gene ontology" (LeGO) vectors for functional gene analysis.
Mol Ther 2008, 16:698–706.
22. Michaelis M, Rothweiler F, Nerreter T, Sharifi M, Ghafourian T, Cinatl J Jr:
Karanjin interferes with ABCB1, ABCC1, and ABCG2. J Pharm Pharm Sci
2014, 17:92–105.
23. Sterz K, Möllmann L, Jacobs A, Baumert D, Wiese M: Activators of
P-glycoprotein: Structure-activity relationships and investigation of their
mode of action. ChemMedChem 2009, 4:1897–1911.
24. Häcker HG, de la Haye A, Sterz K, Schnakenburg G, Wiese M, Gütschow M:
Analogs of a 4-aminothieno[2,3-d]pyrimidine lead (QB13) as modulators
of P-glycoprotein substrate specificity. Bioorg Med Chem Lett 2009,
19:6102–6105.
25. Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, Lamant L,
Meyer N, Gairin JE, Guilbaud N, Annereau JP: Melanoma chemotherapy
leads to the selection of ABCB5-expressing cells. PLoS One 2012, 7:e36762.
26. Brózik A, Hegedüs C, Erdei Z, Hegedus T, Özvegy-Laczka C, Szakács G,
Sarkadi B: Tyrosine kinase inhibitors as modulators of ATP binding
cassette multidrug transporters: substrates, chemosensitizers or inducers
of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011,
7:623–642.
27. Chaudhary PM, Roninson IB: Induction of multidrug resistance in human
cells by transient exposure to different chemotherapeutic drugs. J Natl
Cancer Inst 1993, 85:632–639.
28. Sukhai M, Piquette-Miller M: Regulation of the multidrug resistance genes
by stress signals. J Pharm Pharm Sci 2000, 3:268–280.
29. Cressman AM, Petrovic V, Piquette-Miller M: Inflammation-mediated
changes in drug transporter expression/activity: implications for
therapeutic drug response. Expert Rev Clin Pharmacol 2012, 5:69–89.
doi:10.1186/1756-0500-7-710
Cite this article as: Michaelis et al.: Association between acquired
resistance to PLX4032 (vemurafenib) and ATP-binding cassette
transporter expression. BMC Research Notes 2014 7:710.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
